Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer

Overview

Journal J Pers Med

Date 2021 Nov 27

PMID 34834441

Citations 47

Authors

Gangga Anuraga

Wei-Jan Wang

Nam Nhut Phan

Nu Thuy An Ton

Hoang Dang Khoa Ta

Fidelia Berenice Prayugo

Do Thi Minh Xuan

Su-Chi Ku

Yung-Fu Wu

Vivin Andriani

Muhammad Athoillah

Kuen-Haur Lee

Chih-Yang Wang

Affiliations

Soon will be listed here.

Abstract

Breast cancer remains the most common malignant cancer in women, with a staggering incidence of two million cases annually worldwide; therefore, it is crucial to explore novel biomarkers to assess the diagnosis and prognosis of breast cancer patients. NIMA-related kinase (NEK) protein kinase contains 11 family members named NEK1-NEK11, which were discovered from ; however, the role of NEK family genes for tumor development remains unclear and requires additional study. In the present study, we investigate the prognosis relationships of NEK family genes for breast cancer development, as well as the gene expression signature via the bioinformatics approach. The results of several integrative analyses revealed that most of the NEK family genes are overexpressed in breast cancer. Among these family genes, overexpression had poor prognostic significance in distant metastasis-free survival (DMFS) in breast cancer patients. Meanwhile, had the highest level of DNA methylation, and the functional enrichment analysis from MetaCore and Gene Set Enrichment Analysis (GSEA) suggested that was associated with the cell cycle, G2M checkpoint, DNA repair, E2F, MYC, MTORC1, and interferon-related signaling. Moreover, Tumor Immune Estimation Resource (TIMER) results showed that the transcriptional levels of NEK2 were positively correlated with immune infiltration of B cells and CD4 T Cell. Collectively, the current study indicated that family genes, especially which is involved in immune infiltration, and may serve as prognosis biomarkers for breast cancer progression.

Citing Articles

ST3GAL4 promotes tumorigenesis in breast cancer by enhancing aerobic glycolysis.

Chen X, Su W, Chen J, Ouyang P, Gong J Hum Cell. 2024; 38(1):1.

PMID: 39422756 DOI: 10.1007/s13577-024-01137-z.

Role of NEK2 in tumorigenesis and tumor progression.

Xia J, Zhao H, Edmondson J, Koss B, Zhan F Trends Mol Med. 2024; 31(1):79-93.

PMID: 39181803 PMC: 11717647. DOI: 10.1016/j.molmed.2024.07.013.

Glucosylceramide synthase modulation ameliorates murine renal pathologies and promotes macrophage effector function in vitro.

Cheong A, Craciun F, Husson H, Gans J, Escobedo J, Chang Y Commun Biol. 2024; 7(1):932.

PMID: 39095617 PMC: 11297156. DOI: 10.1038/s42003-024-06606-7.

Identification of metastasis-related genes for predicting prostate cancer diagnosis, metastasis and immunotherapy drug candidates using machine learning approaches.

Wang Y, Ji B, Zhang L, Wang J, He J, Ding B Biol Direct. 2024; 19(1):50.

PMID: 38918844 PMC: 11197330. DOI: 10.1186/s13062-024-00494-x.

Comprehensive bioinformatics analysis of human cytomegalovirus pathway genes in pan-cancer.

Yan T, Pang X, Liang B, Meng Q, Wei H, Li W Hum Genomics. 2024; 18(1):65.

PMID: 38886862 PMC: 11181644. DOI: 10.1186/s40246-024-00633-5.

References

Wu L, Saxena S, Goel P, Prajapati D, Wang C, Singh R . Breast Cancer Cell-Neutrophil Interactions Enhance Neutrophil Survival and Pro-Tumorigenic Activities. Cancers (Basel). 2020; 12(10). PMC: 7599756. DOI: 10.3390/cancers12102884. View

Disis M, Stanton S . Triple-negative breast cancer: immune modulation as the new treatment paradigm. Am Soc Clin Oncol Educ Book. 2015; :e25-30. DOI: 10.14694/EdBook_AM.2015.35.e25. View

Cirillo E, Parnell L, Evelo C . A Review of Pathway-Based Analysis Tools That Visualize Genetic Variants. Front Genet. 2017; 8:174. PMC: 5681904. DOI: 10.3389/fgene.2017.00174. View

Pavan I, Peres de Oliveira A, Dias P, Basei F, Issayama L, de Castro Ferezin C . On Broken Ne(c)ks and Broken DNA: The Role of Human NEKs in the DNA Damage Response. Cells. 2021; 10(3). PMC: 7997185. DOI: 10.3390/cells10030507. View

Lee K, Kuo Y, Ho Y, Huang Y . Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness. Cancers (Basel). 2019; 11(9). PMC: 6769912. DOI: 10.3390/cancers11091334. View

Ioannidou E, Moschetta M, Shah S, Parker J, Ozturk M, Pappas-Gogos G . Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets. Int J Mol Sci. 2021; 22(18). PMC: 8472415. DOI: 10.3390/ijms22189926. View

Luo M, Zeng H, Ma X, Ma X . [Identification of Hub Genes for Ovarian Cancer Stem Cell Properties with Weighted Gene Co-expression Network Analysis]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2021; 52(2):248-258. PMC: 10408925. DOI: 10.12182/20210360205. View

Pang K, Esperto F, Noon A . Opportunities of next-generation sequencing in non-muscle invasive bladder cancer outcome prediction. Transl Androl Urol. 2018; 6(6):1043-1048. PMC: 5760392. DOI: 10.21037/tau.2017.10.04. View

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

10.

Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J . MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2017; 10(3):277-288. DOI: 10.2217/epi-2017-0118. View

11.

Ting G, Li X, Kwon H, Ding T, Zhang Z, Chen Z . microRNA-219-5p targets NEK6 to inhibit hepatocellular carcinoma progression. Am J Transl Res. 2020; 12(11):7528-7541. PMC: 7724362. View

12.

Liu Y, Qi J, Dou Z, Hu J, Lu L, Dai H . Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis. Cell Prolif. 2019; 53(2):e12741. PMC: 7046476. DOI: 10.1111/cpr.12741. View

13.

Cao X, Xia Y, Yang J, Jiang J, Chen L, Ni R . Clinical and biological significance of never in mitosis gene A-related kinase 6 (NEK6) expression in hepatic cell cancer. Pathol Oncol Res. 2011; 18(2):201-7. DOI: 10.1007/s12253-011-9429-0. View

14.

Lin J, Liu T, Yang P . CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study. J Clin Med. 2020; 9(12). PMC: 7763913. DOI: 10.3390/jcm9124019. View

15.

Lv Y, Lv D, Lv X, Xing P, Zhang J, Zhang Y . Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers. Front Genet. 2021; 12:616469. PMC: 8017297. DOI: 10.3389/fgene.2021.616469. View

16.

Pei J, Zhang J, Yang X, Wu Z, Sun C, Wang Z . NEK5 promotes breast cancer cell proliferation through up-regulation of Cyclin A2. Mol Carcinog. 2019; 58(6):933-943. DOI: 10.1002/mc.22982. View

17.

Moniz L, Dutt P, Haider N, Stambolic V . Nek family of kinases in cell cycle, checkpoint control and cancer. Cell Div. 2011; 6:18. PMC: 3222597. DOI: 10.1186/1747-1028-6-18. View

18.

Dai X, Xiang L, Li T, Bai Z . Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. J Cancer. 2016; 7(10):1281-94. PMC: 4934037. DOI: 10.7150/jca.13141. View

19.

Liu L, Hsieh Y, Yang P . Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog)-Driven Gene Signature. J Pers Med. 2020; 10(3). PMC: 7563462. DOI: 10.3390/jpm10030130. View

20.

Wang C, Chang Y, Kuo Y, Lee K, Chen P, Cheung C . Mutation of the PTCH1 gene predicts recurrence of breast cancer. Sci Rep. 2019; 9(1):16359. PMC: 6841698. DOI: 10.1038/s41598-019-52617-4. View